Article
In 1950, three scientists were awarded the Nobel Prize for their groundbreaking discovery of steroids, heralded at the time as a "miracle cure" for rheumatoid arthritis (RA).
All News
Article
Managing health conditions is rapidly evolving as patients increasingly turn to online resources for answers—over 65% search for health-related questions online. Our study analyzed Google search trends for rheumatic disease topics, offering a fascinating glimpse into how online search behavior can reveal patient needs and experiences. This approach, known as "infodemiology," tracks real-time Google Trends data to understand symptom- and treatment-related searches for rheumatic conditions.
Article
Sleep plays a critical role in regulating inflammation and overall health. In rheumatic diseases like lupus and rheumatoid arthritis (RA), disrupted sleep is common and can exacerbate symptoms and disease progression. Experts Dr. Al Kim, Patty Katz, and Dr. Yvonne Lee emphasized the importance of addressing sleep disturbances in these conditions.
Article
Intervention in individuals predisposed to develop RA, with a holy grail of prevention of RA, has long been a hot topic. The 4-year results of the TREAT EARLIER study, presented at Tuesday’s oral abstract session, show that methotrexate appears to prevent the development of RA in high risk ACPA- patients.
Article
Rheumatic diseases, such as axial spondyloarthritis (axSpA) and rheumatoid arthritis (RA), are marked by unpredictable disease flares that adversely impact quality of life and long-term outcomes.
Article
For many women, the journey to motherhood brings a sense of anticipation and joy. However, for those with rheumatoid arthritis, this journey presents unique challenges. At ACR Convergence 2024, researchers discussed how advancements in reproductive medicine and RA management are paving the way for improved outcomes.
Dr. John Cush
Tweet
Methotrexate to Prevent RA, Clear as Mud
Intervention in individuals predisposed to rheumatoid arthritis (RA), aiming for prevention, is a significant topic. Seropositivity for rheumatoid factor and ACPA can precede RA by years. Some patients experience a pre-RA arthralgia… https://t.co/D51CoZAzce https://t.co/lgZalnDeb3
Dr. John Cush
Tweet
Predicting flares in rheumatic diseases with machine learning
Rheumatic diseases, such as axial spondyloarthritis (axSpA) and rheumatoid arthritis (RA), are marked by unpredictable disease flares that adversely impact quality of life and long-term outcomes.… https://t.co/6oFRp0zyBw https://t.co/fcMrJOg4mM
Dr. John Cush
Tweet
Changing Mindsets about Methotrexate Side Effects
Dr. Mrinalini Dey discusses abstract 1676, presented at #ACR24.
https://t.co/8RXBWUioee https://t.co/liQ1hN4Xtr
Dr. John Cush
Tweet
Where there’s smoke, there’s flare: how pollution fuels RA
The WHO has declared climate change to be the greatest threat to human health in the 21st century, likely to contribute to an additional 250,000 deaths annually between 2030 and 2050 #ACR24
https://t.co/efVzSHXN91 https://t.co/AxRyGpqQFa
Dr. John Cush
Tweet
Improving fertility in women with RA
For women with rheumatoid arthritis (RA), the journey to motherhood brings unique challenges, such as longer times to conception and infertility rates twice as high as those without RA. Factors like high disease activity, regular use of… https://t.co/9QXgeB7ftB https://t.co/mVUabSdLNE
Dr. John Cush
Tweet
Playing it Safe with RA? JAK vs. TNF Debate
The ORAL surveillance trial raised safety concerns that the janus kinase inhibitor (JAKi) tofacitinib was associated with an increased incidence of cancer and major adverse cardiovascular events (MACE), compared to tumor necrosis… https://t.co/sUSdRKRxEF https://t.co/XcjOqGlLVX
Dr. John Cush
Tweet
NEW ONLINE POSTER: Safety of a JAKi presented at EULAR 2024!
View safety across 15,000 patient-years of data from 11 Phase 3 trials, including adult patients with RA, PsA, AS, and nr-axSpA. This poster is sponsored by AbbVie US Medical Affairs.
https://t.co/gIFWRqOGmD https://t.co/L0YttKihdf
Dr. John Cush
Tweet
RA Treatment Adherence: Is decision making really shared?
Dr. Jonathan Kay interviews Dr. Cécile Gaujoux-Viala about abstract 0360 at #ACR24.
https://t.co/KwXHutfQko https://t.co/bCVM3JrFEz
Dr. John Cush
Tweet
Treat-to-Target Improves Fertility in Women with RA
Dr. Richard Conway discusses abstract 1647, presented at #ACR24
https://t.co/vC0CA0lN4M https://t.co/Dfo7iBYwcU
Dr. John Cush
Tweet
Addressing CV Risk in RA: Are we doing enough?
The increased risk of cardiovascular disease in patients with rheumatoid arthritis has long been known (1). #ACR24
https://t.co/dajYuK8rpd https://t.co/2Ds3OZEjUX
Dr. John Cush
Tweet
Shedding Weight and Pain: The Promise of Anti-Obesity Medications in RA
For years, rheumatologists have championed weight loss as a cornerstone of care for patients with rheumatoid arthritis (RA) and obesity. RA is an independent risk factor for cardiovascular disease (CVD), a… https://t.co/iozo0FQFzj https://t.co/93e4nZMHJo
Dr. John Cush
Tweet
RheumNow Day 2 Recap: #ACR24 Highlights
Catch the latest insights from the ACR Annual Meeting, where leading experts share groundbreaking research and clinical advances in rheumatology. Don’t miss our live coverage of key takeaways and trends shaping the future of patient care.… https://t.co/F3rZzOTiSJ https://t.co/t3wROMBe7D
Dr. John Cush
Tweet
RA: One JAK to Rule Them All? Dr. Brian Jaros reports on abstract 1362, presented at #ACR24. https://t.co/QChMyma3Y2 https://t.co/qq3BqpT2Gh
Dr. John Cush
Tweet
Finding the Right Combination Therapy in RA
Dr. Jonathan Kay interviews Dr. Ernest Choy about abstract 0521, Transcriptome Analysis of Drug Response in a Large Cohort of Immune-Mediated Inflammatory Disease Patients Supports Advanced Combination Therapy in RA, presented at… https://t.co/yPmDIZ6aKI https://t.co/cairKrbDDu
